Synvista Therapeutics Reports Results Of Three Phase 2 Clinical Trials Of SYI-2074 In Diabetic Patients With Cardiovascular Disease
June 8th, 2008 by 
admin Synvista Therapeutics, Inc. (Amex: SYI) declared accumulation from threesome Phase 2 trials (Trials 201a, 201 and 203) of SYI-2074 in Type 2 diabetic patients. Trial 201a ingrained that haptoglobin (Hp) types, the direct of Synvista’s copyrighted haptoglobin var. effort currently low development, correlated with a disagreement in line levels of ECF isoprostanes, confirming that Hp2-2 in diabetic patients is related with accumulated modify lipids.
Posted in Cardiology | 